MarketCapExport financials
Bioventus (BVS)
The export includes the complete available history of financial statements and ratios. Numbers are provided in full, without million or billion abbreviations, in their original reporting units.
CSV downloads as a ZIP archive with one file for each report and frequency.
Facebook
X
Telegram
Bioventus Income Statement 2025-2011 | BVS
Brief overview of financial performance at Bioventus
The conclusions below are based on five years of reported results. According to figures from Bioventus, revenue changed from 321 million dollars to 568 million dollars over five years. The five-year change reached +76.9%, while CAGR stood at 12.1%. Revenue followed a strong upward trend without signs of stagnation.
Gross profit changed from $234 million to $388 million (+66.2%). The cost base moved against the top-line trend and weighed on the gross result. The gross margin was 72.7% at the start and 68.3% at the end. Weakening gross profitability reduces the quality of the top-line trend.
EBITDA changed from 49.9 million dollars to 101 million dollars (+102.5%). Additional revenue translated efficiently into EBITDA. Comparing the endpoints gives EBITDA margins of 15.5% and 17.8%. The business generated more EBITDA from each unit of revenue.
Over the period, net income shifted from 16.4 million dollars to 22.7 million dollars (+38.5%). Net profit ended the five years at a local peak.
Summary assessment
The results present an uneven picture without one dominant signal. The financial profile benefits from a stronger final result, higher operating efficiency and a larger revenue base. The overall view is constrained by pressure from direct costs. The key question is whether sales can be converted into sustainable profit.
Annual Income Statement Bioventus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
608 M | 589 M | 351 M | 82.3 M | 593 M | - | - | - | - | - | - | - | - | - | - |
Shares |
66.6 M | 64.5 M | 62.6 M | 61.4 M | 45.5 M | - | - | - | - | - | - | - | - | - | - |
Historical Prices |
9.12 | 9.12 | 5.6 | 1.34 | 13 | - | - | - | - | - | - | - | - | - | - |
Net Income |
22.7 M | -36.1 M | -156 M | -159 M | 19.4 M | 16.4 M | 6.85 M | -12.2 M | - | - | - | - | - | - | - |
Revenue |
568 M | 573 M | 512 M | 512 M | 431 M | 321 M | 340 M | 319 M | - | - | - | - | - | - | - |
Cost of Revenue |
180 M | 185 M | 184 M | 181 M | 128 M | 87.6 M | 90.9 M | - | - | - | - | - | - | - | - |
Gross Profit |
388 M | 388 M | 328 M | 331 M | 303 M | 234 M | 249 M | 235 M | - | - | - | - | - | - | - |
Operating Income |
54 M | -15.2 M | -81.7 M | -167 M | 12.1 M | 21.2 M | 31.2 M | - | - | - | - | - | - | - | - |
Interest Expense |
-1.45 M | 1.64 M | 1.29 M | -9.77 M | -1.46 M | 4.43 M | 75 K | - | - | - | - | - | - | - | - |
EBITDA |
101 M | 34.4 M | -24.4 M | -112 M | 46.9 M | 49.9 M | 39.7 M | 36 M | - | - | - | - | - | - | - |
Operating Expenses |
334 M | 403 M | 410 M | 498 M | 291 M | 212 M | 217 M | 208 M | - | - | - | - | - | - | - |
General and Administrative Expenses |
314 M | 344 M | 304 M | 332 M | 254 M | 193 M | 198 M | 192 M | - | - | - | - | - | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Quarterly Income Statement Bioventus
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
68.4 M | 67.9 M | 67.3 M | 139 K | 66.9 M | 66.5 M | 66 M | 313 K | 65.3 M | 64.1 M | 63.4 M | 153 K | 62.8 M | 62.6 M | 62.1 M | 180 K | 61.7 M | 61.5 M | 60.5 M | 3.66 M | 41.8 M | 41.8 M | 41.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Net Income |
6.86 M | 36.2 M | 3.95 M | 17.3 M | 4.01 M | 9.27 M | -3.32 M | -603 K | -5.85 M | -34.2 M | -6.38 M | -7.66 M | -8.79 M | -4.73 M | -174 M | -31.9 M | -108 M | -7.25 M | -14.8 M | -364 K | -1.07 M | -4.13 M | 24.5 M | - | 8.46 M | -5.77 M | 10.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Revenue |
142 M | 153 M | 132 M | 158 M | 139 M | 148 M | 124 M | 154 M | 139 M | 151 M | 129 M | 135 M | 121 M | 137 M | 119 M | 126 M | 129 M | 140 M | 117 M | 130 M | 109 M | 110 M | 81.8 M | - | 85.9 M | 58 M | 78.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Cost of Revenue |
45.3 M | 47.5 M | 41.3 M | 49.1 M | 44.4 M | 45.6 M | 40.8 M | 51 M | 45.4 M | 47.6 M | 41.1 M | 49.1 M | 41.9 M | 47.9 M | 45.1 M | 51.6 M | 44.1 M | 43.7 M | 41.6 M | 42.6 M | 29.8 M | 33.5 M | 22.2 M | - | 23.4 M | 17.7 M | 21.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Gross Profit |
97.1 M | 106 M | 90.8 M | 109 M | 94.2 M | 102 M | 83.1 M | 103 M | 93.6 M | 104 M | 88.4 M | 86.3 M | 78.8 M | 89.1 M | 73.9 M | 74.2 M | 84.5 M | 96.7 M | 75.7 M | 87.8 M | 79.1 M | 76.3 M | 59.6 M | - | 62.5 M | 40.3 M | 57.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Income |
9.7 M | 19.1 M | 8.42 M | 19.5 M | 11.3 M | 18.4 M | 4.87 M | 7.7 M | 3.65 M | -31.5 M | 4.93 M | 1.16 M | 2.42 M | 6.75 M | -92.1 M | -15.6 M | -127 M | -3.31 M | -21.4 M | -3.15 M | -1.05 M | -5.74 M | 22 M | - | 6.93 M | -4.59 M | 13 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Interest Expense |
216 K | 249 K | 427 K | -37 K | -79 K | -561 K | -777 K | 1.24 M | 626 K | -159 K | -63 K | 709 K | -494 K | -513 K | 1.59 M | -9.41 M | -115 K | -604 K | 363 K | 1.36 M | -757 K | -1.64 M | -419 K | - | 3.28 M | 1.34 M | -2.46 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
EBITDA |
10.7 M | 20.2 M | 9.52 M | 54 M | 12.6 M | 19.8 M | 6.46 M | 40.8 M | 5.71 M | -29.4 M | 6.68 M | 39.7 M | 4.74 M | 9.04 M | -89.9 M | 31.9 M | -125 M | -612 K | -18.2 M | 26.7 M | 831 K | -3.89 M | 23.9 M | - | 28.7 M | 9.92 M | 20.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Operating Expenses |
87.4 M | 86.5 M | 82.4 M | 89.3 M | 83 M | 83.7 M | 78.2 M | 95 M | 89.9 M | 135 M | 83.5 M | 85.1 M | 76.4 M | 82.4 M | 166 M | 89.8 M | 211 M | 100 M | 97.2 M | 90.9 M | 80.1 M | 82.1 M | 37.6 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
General and Administrative Expenses |
82.9 M | 82.7 M | 78.3 M | 82.8 M | 78.7 M | 79.1 M | 73.5 M | 86.9 M | 81.5 M | 96.7 M | 78.8 M | 78.4 M | 69.8 M | 74.8 M | 80.9 M | 77.4 M | 79 M | 89.6 M | 86.1 M | 80.9 M | 69.6 M | 69 M | 34.7 M | - | 50.3 M | 40.5 M | 40.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
The income statement is one of the three key financial reports of a company Bioventus (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Diagnostics research industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Enzo Biochem
ENZ
|
- | -8.98 % | $ 14.8 K |  USA |
 |
Waters Corporation
WAT
|
$ 476.29 | -0.09 % | $ 28.4 B | USA |
 |
Exagen
XGN
|
$ 5.26 | -25.92 % | $ 113 M | USA |
 |
Celcuity
CELC
|
$ 67.13 | -4.11 % | $ 3.14 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
$ 370.89 | -0.25 % | $ 30.9 B | USA |
 |
Lantheus Holdings
LNTH
|
$ 101.65 | 0.63 % | $ 6.86 B | USA |
 |
Accelerate Diagnostics
AXDX
|
- | -61.36 % | $ 2.46 M | USA |
 |
Medpace Holdings
MEDP
|
$ 664.97 | -1.18 % | $ 19.2 B | USA |
 |
Charles River Laboratories International
CRL
|
$ 346.21 | -2.02 % | $ 17.2 B | USA |
 |
Mettler-Toledo International
MTD
|
$ 1 750.2 | -0.69 % | $ 36.1 B |  Schweiz |
 |
Danaher Corporation
DHR
|
$ 236.19 | 0.46 % | $ 168 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
$ 30.39 | -1.32 % | $ 28.8 B |  Niderland |
 |
RadNet
RDNT
|
$ 77.91 | -0.6 % | $ 5.86 B | USA |
 |
Senseonics Holdings
SENS
|
$ 10.05 | 2.55 % | $ 419 M | USA |
 |
Neuronetics
STIM
|
$ 2.01 | -7.8 % | $ 133 M | USA |
 |
T2 Biosystems
TTOO
|
- | -39.35 % | $ 313 K | USA |
 |
Thermo Fisher Scientific
TMO
|
$ 719.09 | -0.35 % | $ 271 B | USA |
 |
Biocept
BIOC
|
- | -13.05 % | $ 7.29 M | USA |
 |
Guardant Health
GH
|
$ 155.43 | -2.12 % | $ 19.5 B | USA |
 |
Akumin
AKU
|
- | -17.87 % | $ 25.9 M |  Canada |
 |
Brainsway Ltd.
BWAY
|
$ 10.63 | -8.68 % | $ 361 M |  Israel |
 |
VolitionRx Limited
VNRX
|
$ 0.19 | -6.2 % | $ 23.9 M |  Singapore |
 |
Natera
NTRA
|
$ 311.81 | -1.92 % | $ 42.6 B | USA |
 |
IQVIA Holdings
IQV
|
$ 275.46 | -1.21 % | $ 47.4 B | USA |
 |
Agilent Technologies
A
|
$ 178.84 | -0.74 % | $ 50.8 B | USA |
 |
Quotient Limited
QTNT
|
- | -11.32 % | $ 1.1 M | Schweiz |
 |
Chembio Diagnostics
CEMI
|
- | 0.22 % | $ 16.8 M | USA |
 |
DermTech
DMTK
|
- | -11.32 % | $ 2.94 M | USA |
 |
Surmodics
SRDX
|
- | - | $ 608 M | USA |
 |
Invitae Corporation
NVTA
|
- | - | $ 21.2 M | USA |
 |
Syneos Health
SYNH
|
- | - | $ 4.46 B | USA |
 |
Motus GI Holdings
MOTS
|
- | -34.28 % | $ 263 K | Israel |
 |
Heska Corporation
HSKA
|
- | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
- | -20.0 % | $ 1.06 M | USA |
 |
Renalytix AI plc
RNLX
|
- | 5.66 % | $ 22.7 M |  Britain |
 |
Psychemedics Corporation
PMD
|
- | -1.84 % | $ 15.3 M | USA |
 |
Meridian Bioscience
VIVO
|
- | - | $ 1.49 B | USA |
 |
DexCom
DXCM
|
$ 79.92 | -1.42 % | $ 31.2 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
$ 258.38 | -0.5 % | $ 28.7 B | USA |
 |
Castle Biosciences
CSTL
|
$ 34.41 | 0.07 % | $ 997 M | USA |
 |
IDEXX Laboratories
IDXX
|
$ 696.77 | -1.4 % | $ 56 B | USA |
 |
Illumina
ILMN
|
$ 214.84 | -2.69 % | $ 33.3 B | USA |
 |
Anixa Biosciences
ANIX
|
$ 3.05 | -3.48 % | $ 99 K | USA |
|
Biodesix
BDSX
|
$ 10.04 | -2.95 % | $ 75.8 M | USA |
 |
BioNano Genomics
BNGO
|
$ 1.25 | 7.66 % | $ 6.81 M | USA |
 |
Fulgent Genetics
FLGT
|
$ 25.83 | -1.22 % | $ 795 M | USA |
 |
CareDx, Inc
CDNA
|
$ 80.78 | -4.31 % | $ 4.3 B | USA |
 |
Oxford Immunotec Global PLC
OXFD
|
- | - | $ 562 M | Britain |
 |
Biomerica
BMRA
|
$ 1.48 | -4.52 % | $ 4.31 M | USA |